



PHARMACEUTICALS EXPORT PROMOTION COUNCIL

(Set up by Ministry of Commerce, Govt. of India)

COPY

Date : 02-06-2010

News / Story reproduced with thanks:- **Pharmabiz**

NPPA to finalise first pharmaceutical census of India soon

Wednesday, June 02, 2010 08:00 IST **Ramesh Shankar, Mumbai**

Direct link to the News/Story:-

<http://www.pharmabiz.com/article/detnews.asp?articleid=55744§ionid=>

The National Pharmaceutical Pricing Authority (NPPA) will soon finalise the first pharmaceuticals census of India (FPCI), for which the national drug price regulator had launched a campaign way back in February 2008 to develop a comprehensive and dependable database to help policy-makers and other stakeholders.

According to sources, the NPPA has already collected data from 6299 pharma units scattered all over the country through structured questionnaires under the FPCI. It will soon prepare the final report after getting the data compiled and processed by an agency for which the NPPA has already issued an expression of interest.

Based on the filled in questionnaires canvassed for the FPCI, the agency will engage in compilation/tabulation of data already collected by NPPA from 6299 pharma units through questionnaires, generating desired tables, writing report and will also be engaged in collecting data from left-over units, and amalgamation of the entire collected data.

The final report will provide a pharmaceutical map of India that will exhibit and illuminate all those districts of the country where pharmaceutical manufacturing units exist. It will detail about the investment in plant & machinery, land & building by pharma manufacturing units in the country by class of industry (tiny, small/medium and large) at disaggregated levels of administrative set-up (state-wise/district-wise) and the turnover of the units by class of industry, state-wise and district-wise and also by type of units i.e. formulation or bulk drugs.

The final report on the FPCI will explain about state-wise and district-wise employment generated in the country by the pharma sector, by class of industry, gender-wise, and also by type of units. It will provide state-wise and district-wise details on the number of 'own' and 'loan' licenses and also by type of units issued by various state drug controllers. There will be state-wise and district-wise details on the distribution of pharma manufacturing units by capacity installed, capacity utilized by major products; distribution of manufacturers by number of formulations within the ambit of DPCO and by category of industry; distribution of manufacturers by number of formulations outside the domain of DPCO and by category of industry; and also distribution of manufacturers by number of total formulations (both DPCO and non-DPCO) and by category of industry.

The final report will give details about the state-wise and district-wise pattern of consumption of inputs by source (indigenous/ imported) by manufacturing units; pattern of consumption of 'utilities' (e.g. power, water, fuel) by manufacturing units; pattern of expenditure on R&D, clinical trials and quality control; and pattern of inventory of semi-finished goods, finished products. There will be details about the working capital, loans outstanding and interest accrued; and distribution of manufacturing units by number of

products.

It will also have details about the distribution of number of manufacturing units who hold WHO-GMP certification and the number and pattern of export-oriented pharma manufacturing units and countries of destinations.